-
1 week ago | 
bioworld.com | Nuala Moran
Home » Brink’s recombinase enzymes offer new gene editing approachBrink’s recombinase enzymes offer new gene editing approachNewco Brink Therapeutics SAS is poised to work on the next chapter in genome editing after raising €3.5 million (US$4 million) in seed funding to discover and develop programmable recombinase enzymes. BioWorld Financings Newco news Cancer CAR T Seed Europe
-
1 week ago | 
bioworld.com | Nuala Moran
M42 enters R&D with investment in longevity firm JuvenescenceThe Abu Dhabi health care company M42 is to make an investment in U.K.-based longevity specialist Juvenescence as a route to moving into drug discovery and development, with the two forming a partnership to work together on products that extend the healthy lifespan and improve the treatment of chronic diseases. BioWorld Science Deals and M&A Financings Aging Series B Europe
-
1 week ago | 
bioworld.com | Nuala Moran
Home » Cyprumed, Merck ink $493M peptide pill licensing deal BioWorld briefs for April 15, 2025. BioWorld MedTech briefs for April 15, 2025. At first glance, it appears that biopharmaceuticals dodged the latest U.S. tariff bullet; med-tech, not so much. According to the executive order President Donald... U.S. tariffs on biopharmaceuticals have advanced beyond administration talking points.As a precursor to tariffs, Commerce Secretary Howard Lutnick initiated an...
-
1 week ago | 
bioworld.com | Nuala Moran
Cyprumed, Merck ink $493M peptide pill licensing deal Oral peptide delivery specialist Cyprumed GmbH is about to find out if the high bioavailability of its tablet formulations seen in animal models will translate across to humans, after signing a $493 million license and option agreement with Merck & Co. Inc. BioWorld Deals and M&A Endocrine/metabolic Peptide Europe U.S.
-
1 week ago | 
bioworld.com | Nuala Moran
New UK law aims for ‘faster, fairer and more inclusive’ clinical trialsAs new clinical trials regulations were signed into law in the U.K., an analysis of 4,616 submissions to conduct studies has highlighted what is required for the updated law to translate into a more efficient, streamlined and adaptable regulatory framework. BioWorld Regulatory Cancer Europe MHRA Policy
-
1 week ago | 
bioworld.com | Nuala Moran
Home » Novartis boosting US manufacturing with $23B investment BioWorld briefs for April 10, 2025. BioWorld MedTech briefs for April 10, 2025. Lyme disease is a multisystemic zoonotic infection caused by Borrelia burgdorferi bacteria transmitted by ticks. Lyme disease is a public health problem because... At first glance, it appears that biopharmaceuticals dodged the latest U.S. tariff bullet; med-tech, not so much. According to the executive order President Donald...
-
2 weeks ago | 
bioworld.com | Nuala Moran
UK government invests £500M in health data research serviceThe U.K. government is to invest £500 million (US$645 million) in a health data research service that will provide a single point of access to national-scale anonymized patient records, ending the need to navigate different systems or make multiple applications to use information. BioWorld Clinical Europe U.S.
-
2 weeks ago | 
bioworld.com | Nuala Moran
Experts cite deadly consequences of PEPFAR funding disruptionThe extent of the damage that will be caused if the U.S. overseas aid program, the President’s Emergency Plan for AIDS Relief (PEPFAR), is axed or has its funding cut, is laid out in an expert analysis published in The Lancet April 8, which estimates nearly 500,000 children could die from AIDS-related causes by 2030, while 1 million children will be infected with the virus. BioWorld Infection HIV/AIDS U.S.
-
2 weeks ago | 
bioworld.com | Nuala Moran
Women's healthWomen’s health needs a ‘GLP-1 moment’ to attract investors“Men in general have been playing golf for a longer time – in those old boy networks we still haven’t tapped into.” It may seem far-fetched, but that is put forward as a reason for underinvestment in women’s health companies. The argument goes that women heading women’s health startups find it hard to raise money because their networks are weaker, making it harder to tap into investment networks.
-
2 weeks ago | 
bioworld.com | Nuala Moran
Women’s health needs a ‘GLP-1 moment’ to attract investors“Men in general have been playing golf for a longer time – in those old boy networks we still haven’t tapped into.” It may seem far-fetched, but that is put forward as a reason for underinvestment in women’s health companies. The argument goes that women heading women’s health startups find it hard to raise money because their networks are weaker, making it harder to tap into investment networks.
